187P - Common and Rare Egfr Mutations in Non-Small Cell Lung Cancer

Abstract

ABSTRACT Background: In non-small cell lung cancer (NSCLC), the association between common EGFR mutations (Del EX19/ L858R) with EGFR tyrosine kinase inhibitors (EGFR-TKIs) has been well established. Not so for rare EGFR mutations, not even their impact on treatment response to platinum-based chemotherapy. Methods: We analyzed 188 NSCLC patients’ harbouring EGFR mutations from Mexico, Colombia and Costa Rica. Patients were treated according to international guidelines for the treatment of lung cancer. As first line treatment, 64.1% receive platinum-based chemotherapy and 30.8% receive EGFR-TKIs, after chemotherapy progression. Clinical-pathological characteristics and presence of common and rare EGFR mutations regarding treatment response were analysed. Protocol is registered with ClinicalTrials.gov, number NCT01023828. Results: Of all patients, 79.5% had common and 20.5% had rare EGFR mutations. Lepidic and acinar adenocarcinoma were associated with common EGFR mutation (p = 0.010). Patients who harboured common EGFR mutations had higher response rates to EGFR-TKIs versus those who had rare EGFR mutations (63.8% cf 32.4%, p Conclusions: Our findings suggested that patients who harboured rare EGFR mutations only could receive platinum-based chemotherapy as first-line treatment and EGFR-TKIs could be reserved as second- or third-line treatment. Disclosure: All authors have declared no conflicts of interest.